Alzamend Neuro (ALZN) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $26.00 from $25.00 | Aug 19, 2026 |
| Ascendiant Capital | Maintained | Buy | $28.00 from $42.00 | Dec 22, 2025 |
| Ascendiant Capital | Maintained | Buy | $42.00 from $45.00 | Sep 25, 2025 |
| Ascendiant Capital | Maintained | Buy | $45.00 from $180.00 | Aug 21, 2025 |
| Ascendiant Capital | Maintained | Buy | $20.00 from $32.00 | Mar 17, 2025 |
| Ascendiant Capital | Maintained | Buy | $32.00 from $35.00 | Dec 16, 2024 |
| Ascendiant Capital | Maintained | Buy | $35.00 from $50.00 | Nov 11, 2024 |
Frequently asked questions
Is ALZN a buy, sell, or hold?
Analysts covering Alzamend Neuro currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ALZN?
On Aug 19, 2026, Ascendiant Capital maintained Alzamend Neuro at Buy with a price target of $26.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.